Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.27375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review.
Diabetes Obes Metab
January 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Despite the recognition by key guidelines that achieving early glycaemic control has important benefits in individuals with type 2 diabetes (T2D) and that addressing excess adiposity is one of the central components of comprehensive person-centred T2D care, a substantial proportion of individuals with T2D do not meet their metabolic treatment goals. Prior treatment paradigms were limited by important treatment-associated risks such as hypoglycaemia and body weight gain. Therefore, a more conservative, sequential approach to treatment was typically utilized.
View Article and Find Full Text PDFModulation of GABAergic system as a therapeutic option in stroke.
Exp Neurol
February 2025
Department of Neurology, Louisiana State University Health Science Center, Shreveport, LA, USA. Electronic address:
Article Synopsis
- Stroke is a major global health issue, leading to high mortality and disability rates, with current treatment methods failing to significantly improve long-term recovery outcomes.
- Recent research highlights the importance of the GABAergic neurotransmission system in enhancing functional recovery post-stroke, suggesting it merits further exploration.
- The review discusses GABA modulating therapies, particularly neurosteroids, and emphasizes the need for more research to develop effective treatments tailored to factors like age and sex in stroke patients.
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
eNeuro
September 2024
Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the GH Sergievsky Center, Columbia University Irving Medical Center, New York, New York 10032
Article Synopsis
- The FDA approved aducanumab in 2021, marking a significant breakthrough in Alzheimer's disease treatment, with two more drugs, lecanemab and donanemab, receiving similar approvals in early 2023 and mid-2024.
- These therapies, which target β-amyloid aggregates, have shown promising results in slowing cognitive decline in clinical trials.
- Ongoing discussions focus on the application of trial results to real-world scenarios and the overall long-term benefits of these treatments, along with the implications of FDA approval conditions on their usage in clinical practice.
Disease burden and healthcare utilization in pediatric low-grade glioma: A United States retrospective study of linked claims and electronic health records.
Neurooncol Pract
October 2024
Day One Biopharmaceuticals, Inc., Brisbane, California, USA (S.Z., T.C., S.Y., P.M., M.K., S.G.R.).
Background: Despite high long-term survival rates, pediatric low-grade gliomas (pLGGs) are linked with significant tumor- and treatment-associated morbidities that may persist throughout life. The aims of this descriptive cross-sectional pilot study were to characterize health conditions among a cohort of patients with pLGG and explore the feasibility of quantifying disease burden and healthcare resource utilization (HRU).
Methods: Optum Market Clarity Data were used to identify patients aged ≤18 years with an ICD-10 code for brain neoplasm, ≥1 physician notes, and with evidence of pLGG recorded between January 1, 2017 and June 30, 2018.
Current developments in prehabilitation in urologic oncology.
Curr Opin Urol
November 2024
Department of Urology, University of Washington School of Medicine.
Purpose Of Review: Prehabilitation describes interventions that are undertaken prior to a major surgical or medical intervention with the objective of improving functional capability with the goal of improving candidacy for therapy, bolstering one's ability to withstand treatment-associated toxicity, functional decline, and facilitating accelerated recovery. The objective of this review is to detail the key tenets of prehabilitation, synthesize contemporary advances in prehabilitation science within Urologic Oncology , and discuss key methodologic trial design considerations salient to future prehabilitation investigations.
Recent Findings: Contemporary prehabilitation clinical trials have primarily evaluated unimodal interventions aiming to improve functional capacity across the domains of physical exercise, nutrition, and cognition with heightened interest in evaluating multimodal interventions addressing two or more domains.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!